China gene editing startup YolTech raises $70M to move CRISPR therapies forward
One of China’s most prolific gene editing companies has raised its biggest round of funding yet, ahead of plans to go public in Hong Kong. While most gene editing companies in the US trimmed their ...
YolTech Therapeutics CEO Yuxuan Wu (L) and chief technology officer Zi Jun Emma Wang May 28, 2026 08:30 AM EDTUpdated May 28, 08:41 PM FinancingR&DCell/Gene Tx Exclusive: China gene editing startup YolTech raises $70M to move CRISPR therapies forward Ryan Cross Senior Science Correspondent One of China’s most prolific gene editing companies has raised its biggest round of funding yet, ahead of plans to go public in Hong Kong. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that